Blog | Apr. 10, 2023
Liquid biopsy with Plasma-Safe-SeqS
Sysmex Inostics empowers accurate detection of low-frequency biomarkers from a simple blood draw.
Our lab runs blood-based biomarker analyses to detect, track, and monitor relevant mutations in circulating tumor DNA (ctDNA) at low levels (0.03-0.05%) with high specificity.
• Detect earlier
• Monitor easily
• Partner confidently
• Leader in ultra-sensitivity
Our video presentation illustrates how our Plasma-Safe-SeqS NGS technology can detect clinically relevant mutations in ctDNA as low as 0.03%* mutant allele frequency (MAF). Plasma-Safe-SeqS ensures reliable molecular information for real-time therapy selection as well as monitoring of tumor response.
Expedite your clinical studies and uncover deeper insights into therapy response.
*For input of 20,000 genomic equivalents